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ABSTRACT 
Background:  Despite that the epidemiological studies on the comorbidity of alcohol misuse 
and psychiatric disorders have been studied, less is known about the magnitude of these 
disorders among patients with alcoholic liver disease (ALD).  Our aim was to determine the 
prevalence of psychiatric and substance use disorders among hospitalized ALD patients in the 
US.     
Methods: We utilized a single level clinical classification software to identify patients with ALD 
and psychiatric/substance use disorders from the 2011 National Inpatient Sample data.  The 
primary outcome was the prevalence of these disorders among hospitalized patients with ALD 
(n=74,972) compared to those with chronic liver diseasesnot caused by alcohol (n=350,140) 
and those without underlying liver diseases (n=1,447,063).       
Results:  The prevalence of adjustment disorder, anxiety disorder, post-traumatic stress 
disorder and depression was significantly higher among hospitalized patients with ALD when 
compared to those with chronic liver diseases not caused by alcohol (all with p values <0.05).  
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Younger age, female gender, and White race were the independent predictors of 
psychiatric/substance use disorders among hospitalized patients with ALD.    
 Conclusions:  Hospitalized patients with ALD have significantly high prevalence of concomitant 
psychiatric and substance abuse disorders when compared to those with chronic liver diseases 
not caused by alcohol and those without underlying liver diseases.  Screening and appropriate 
intervention should be implemented as part of routine clinical care for these patients.  
 
INTRODUCTION 
Excessive alcohol consumption can cause diseases with significant economic and social 
burdens (Basra and Anand, 2011; Rehm et al., 2013).  Recent data showed that approximately 
6% of all global deaths were attributed to alcohol consumption ( World Health Organization, 
2015).  Alcoholic liver disease (ALD) is a main cause of alcohol-related morbidity accounting for 
48% of all deaths from cirrhosis (Rehm et al., 2013).  It consists of a spectrum of disorders 
ranging from alcohol-induced fatty liver to alcoholic hepatitis and cirrhosis. Alcoholic steatosis, 
once considered benign, is now recognized as a condition that may lead to advanced liver 
disease or cirrhosis (Teli et al., 1995).  At present, there are no specific pharmacotherapies for 
patients with ALD.  In those with advanced and decompensated liver disease, liver 
transplantation has been shown to improve the overall outcomes and survival (Mathurin and 
Bataller, 2015; Varma et al., 2011).  Abstaining from alcohol is the cornerstone in the 
management of ALD.  A French study showed the improvement in Child-Pugh scores in 66% of 
subjects with ALD who became abstinent (Veldt et al., 2002). 
One of the major problems in the management of patients with ALD is the relapse to 
harmful drinking after abstinence (Cuadrado et al., 2005; Egawa et al., 2014).  Alcohol use 
relapse is a risk factor for hepatic decompensation and recurrent alcoholic hepatitis (Potts et al., 
2013).  In post liver transplant patients, it can lead to poor compliance to medical care, graft 
loss, and impaired long-term survival (Cuadrado et al., 2005; Egawa et al., 2014; Hartl et al., 
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2011; Pfitzmann et al., 2007).  Several factors predicting relapse include a family history of 
alcohol abuse/dependence, lack of self-perception of having an alcohol drinking problem, a poor 
social support system, the duration of abstinence before liver transplantation, and underlying 
psychological disorders (other than alcohol abuse/dependence)(Dew et al., 2008; Egawa et al., 
2014; Hartl et al., 2011).       
Previous reports have shown that those with alcohol misuse/dependence are more 
likely to have other psychiatric conditions such as major depressive disorder, generalized 
anxiety disorder, and post-traumatic stress disorder compared to those without alcohol 
dependence ( Petrakis IL et al.,2002; Kessler et al., 1996; Regier et al., 1990).  Although 
psychological as well as pharmacological therapies for psychiatric disorders and alcohol use 
disorders can be offered to assist these patients, they frequently do not receive treatment(s) 
addressing both conditions ( Petrakis IL et al., 2002).  Despite epidemiological studies on the 
comorbidity of alcohol misuse and psychiatric disorders (Petrakis IL et al., 2002; Kessler et al., 
1996; Regier et al., 1990), less is known about the prevalence of psychiatric disorders among 
patients with ALD.  Understanding the scope of these problems among ALD patients is essential 
to develop comprehensive plans that address both alcohol and psychiatric disorders.  The 
objective of our study was to determine the co-occurrence of psychiatric disorders among 
hospitalized ALD patients in the US.      
METHODS 
Data source 
The National Inpatient Sample (NIS) 2011 data were used for the analyses.  The NIS is 
the largest publicly available all-payer inpatient healthcare database, which was collected as 
part of the Healthcare Cost and utilization project (HCUP) by the Agency for healthcare 
Research and Quality (Healthcare Cost and Utilization project ., 2016).  The data contain 8 
million hospital stays from about 1,000 hospitals sampled to approximate a 20-percent 
stratified sample of U.S. community hospitals.  In the NIS data, the U.S. community hospitals are 
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divided into strata using five hospital characteristics: ownership/control, bed size, teaching 
status, urban/rural location, and U.S. region.  The sampling probabilities are proportional to the 
number of U.S. community hospitals in each stratum.  Weights were provided to calculate 
national estimates.  Sampling of hospitals and sample weights of the NIS data are described 
elsewhere (Healthcare Cost and Utilization project ., 2016). 
Study cohort and variables identification 
We identified 3 cohorts from the NIS 2011 data using the International Classification of 
Diseases-Ninth Revision, Clinical Modification (ICD-9-CM).  The first cohort was patients with 
alcoholic hepatitis/cirrhosis and those with the diagnosis of alcohol-related disorder (as defined 
by ICD 9 codes in supplementary table 1) who presented with elevated liver enzymes in the 
absence of other liver etiologies such as viral hepatitis, biliary cirrhosis, autoimmune liver 
disease, nonalcoholic cirrhosis, etc.  The second cohort was hospitalized patients with other 
chronic liver diseases (such as non-alcoholic steatohepatitis, hepatitis C infection, and biliary 
cirrhosis) not caused by alcohol   Any patients who had the diagnosis of alcohol dependence 
syndrome, nondependent alcohol abuse, and toxic effect of alcohol were excluded.   For the last 
cohort, we randomly selected 5% of all hospitalized subjects with no known liver diseases.       
We used the single level clinical classification software category to identify subjects with 
psychiatric and non-alcohol related substance use disorders.  This software provides collapsed 
clinically meaningful categories of over 14,000 diagnostic codes as well as 3,900 procedural 
codes.  The ICD-9-CM codes which were used in our study are provided in supplementary 
table 1.   
Statistical analyses 
All statistical analyses were performed using SAS 9.3 software (Cary, NC) accounting for 
the sampling weights and stratified sample design of the NIS data to attain nationally 
representative estimates (Healthcare Cost and Utilization project , 2016) .  Basic descriptive 
statistics such as mean and standard deviation (for continuous variables) and percentages (for 
categorical variables) were used to describe the study cohorts. 
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The primary outcome of interest was the prevalence of psychiatric/mental disorders in 
hospitalized patients among the 3 cohorts.  Chi-square (χ2) analyses were used to compare the 
differences in the prevalence between/among groups.  Logistic regression analyses adjusting 
for potential covariates such as age, sex, race, and income quartile were used to determine the 
independent predictors of psychiatric/mental disorders.   All the analyses were two-tailed.  The 
p value less than 0.05 was considered statistically significant.  
RESULTS 
Demographic characteristics of the study cohorts   
The detailed characteristics of the study cohorts are summarized in Table 1.  Patients 
with ALD were younger (53.3±0.2 yrs) than those with chronic liver diseases not caused by 
alcohol (58.8±0.4 yrs) and those without underlying liver diseases (57.6±0.4 yrs).  Among 
patients with ALD, most were men (71%), and White (69%).  While Medicare was the primary 
payer (~45%) for patients with chronic liver disease not caused by alcohol, , only 29% of 
patients with ALD were covered by Medicare (p<0.001). 
Prevalence of psychiatric/non-alcohol related substance use disorders among study 
cohorts 
The prevalence of adjustment disorder (0.58 vs. 0.42), anxiety disorder (8.84 vs 7.54), 
mood disorders (24.3 vs. 18.7), personality disorder (0.96 vs. 0.73), non-alcohol related 
substance abuse (12.4 vs. 9.9), suicide-related disorder (2.4 vs 1.1), tobacco use (43.8 vs. 27.8), 
post-traumatic stress disorder (1.14 vs. 0.82), and depression (3.9 vs. 2.1) was significantly 
higher among hospitalized patients with ALD when compared to those with chronic liver 
diseases not caused by alcohol (all with respective p value <0.05)(Table 2).  The prevalence of 
attention deficit disorder (0.54 vs. 0.43), delirium disorder (7.11 vs. 2.91), developmental 
disorder (0.8 vs. 0.5), impulse disorder (0.12 vs. 0.03), personality disorder (1.28 vs. 0.96), and 
schizo/psychotic disorder (3.44 vs. 2.35) was significantly higher in hospitalized ALD patients 
when compared to those without underlying liver diseases (Table 2).  Given the high 
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prevalence of hepatitis C infection among patients with ALD, we also performed a separate 
analysis including patients with combination of ALD and hepatitis C infection, compared to 
those with chronic liver diseases not caused by alcohol.  The results are shown in 
supplementary table 2. 
Evaluation of the relationship between ALD and psychiatric/non-alcohol related 
substance abuse disorders by multivariate logistic regression    
We next assessed the association between psychiatric/non-alcohol related substance 
use disorders in patients with the diagnosis of ALD compared to those with chronic liver 
diseases not caused by alcohol, those without underlying liver diseases using multivariate 
logistic regression models adjusting for potential covariates including age, sex, race, and income 
quartile (Table 3).  Patients with ALD were 1.16, 1.37, 1.83, 1.76, 1.72, and 1.17 times more 
likely to have anxiety disorder, mood disorder, depression, suicide-related disorder, tobacco 
use, and post-traumatic stress disorder compared to those with chronic liver diseases not 
caused by alcohol(Table 3).  Similar findings were found when we compared patients with ALD 
and those without underlying liver diseases, except that those without underlying liver diseases 
had less risk for suicide-related disorders (OR 0.81) when compared to those with ALD (Table 
3).  
Predictors of psychiatric/non-alcohol related substance use disorders among 
hospitalized patients with ALD 
We next determined the predictors of psychiatric/non-alcohol substance use disorders 
among hospitalized patients with ALD (Table 4).  There was an inverse association between 
patient’s age and psychiatric/non-alcohol substance use disorders (aOR 0.97, 95%CI 0.96-0.97).  
When compared to Caucasians, Blacks (aOR 0.80, 95%CI 0.73-0.88) and Hispanics (aOR 0.56, 
95%CI 0.51-0.61) had less risk for psychiatric/non-alcohol related substance use disorders.  
Women had a significantly higher risk for psychiatric/non-alcohol related substance use 
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disorders than men (aOR 1.58, 95%CI 1.51-1.66) .   We did not observe the levels of income as 
an independent predictor for these disorders.   
DISCUSSION   
In our present study, we aimed to determine the magnitude of psychiatric and non-
alcohol related substance use disorders among patients with ALD.  The major findings of our 
study are as follows: 1) hospitalized ALD patients had significantly higher prevalence of several 
psychiatric and substance use disorders when compared to those with chronic liver diseases not 
caused by alcohol and those without underlying liver diseases and , 2) the presence of these 
disorders is most commonly seen in young Caucasian females with ALD.    
Co-occurrence of psychiatric illnesses is not uncommon in patients with alcohol use 
disorder (Kessler et al., 1996; Regier et al., 1990; Helzer and Pryzbeck, 1988).  In a large 
epidemiologic study in the US, underlying psychiatric disorders, notably antisocial personality, 
affective and anxiety disorders, were found in 37% among patients with alcohol use disorders 
(Regier et al., 1990).  While the association between alcohol use and psychiatric disorders is 
well described (Kessler et al., 1996; Regier et al., 1990), less is known about the prevalence of 
psychiatric and substance use disorders in patients with ALD.  We found a higher prevalence of 
several psychiatric and substance use disorders among hospitalized patients with ALD.  Our 
results have several clinical implications.  ALD patients seldom volunteer specific information or 
problems about their underlying drinking or psychiatric issues, unless they are asked (Helzer 
and Pryzbeck, 1988); however, even if they do, these patients may be in denial or trying to 
minimize the magnitude of the problems.    Our data suggest that screening for underlying 
psychiatric disorders should be implemented as part of routine clinical cares of patients with 
ALD.     Achieving long-term abstinence is the cornerstone of management for patients with ALD. 
If underlying psychiatric illnesses are undiagnosed, these patients will not receive appropriate 
treatment and likely relapse to alcohol use as a means of coping (Cuadrado et al., 2005; Hartl et 
al., 2011).  Therefore, it is crucial for hepatologists to gather comprehensive mental health 
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information when assessing patients with ALD.  Specific inquiries focusing not only on the 
quantity and patterns of alcohol use but also on screening questions to evaluate for possible co-
occurrence of underlying psychiatric disorders are needed and should be part of routine 
hepatology practice.  Those with positive screens   should be further evaluated for definitive 
diagnosis and treatment.  Our results also provide certain patient characteristics (i.e., younger 
age, Caucasians, and female patients) which are independently associated with psychiatric and 
substance use disorders among patients with ALD. Special focus with extensive screening may 
be needed when we encounter patients with ALD having these characteristics to uncover 
possible underlying psychiatric issues. 
The strengths of our study are the careful selection of the study cohort and its large 
sample size representing hospitalized patients in the US.  However, our study also has several 
limitations.  First, the prevalence of psychiatric disorders in our study is limited to those who 
were hospitalized.  Further, the NIS data do not capture hospitalizations from Veterans Affairs 
hospital, short-term rehabilitation hospitals, long-term non-acute care hospitals, psychiatric 
hospitals, and alcoholism/chemical dependency treatment centers.  There is also a possibility of 
underreporting of psychiatric and substance use disorders in our study cohorts.  Therefore our 
results may be different if the study were performed in an outpatient-based or in specialized 
institutes.  Second, laboratory tests are not available in the NIS data so we are not able to 
determine the severity of underlying ALD and its contribution to our findings.  Third, each NIS 
data entry is equivalent to one hospitalization. It is plausible that one patient may contribute to 
multiple entries if he/she was re-hospitalized within the study period.  Fourth, there is a 
possibility of misclassification of the study subjects when we used ICD-9CM coding to identify 
our study cohorts and underlying psychiatric and substance use disorders.   
In conclusion, we found significantly higher prevalence of several psychiatric and 
substance use disorders among hospitalized patients with ALD when compared to those with 
chronic liver diseases not caused by alcohol and those without underlying liver diseases.  
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Screening and appropriate intervention should be implemented as part of routine clinical care 
for these patients.   
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TABLE 1:  Baseline demographic characteristics of the study cohort  
 
Alcoholic liver 
disease 
(N= 74,972) 
Liver diseases from 
other etiologies, not 
caused byalcohol 
(N= 350,140) 
p value** Hospitalized 
patients without 
underlying liver 
diseases 
(N= 1,447,063)  
p 
value** 
Age in years 
(mean ± SD) 
53.3 ± 0.2 58.8 ± 0.4 
<0.001 
57.6 ± 0.4 
<0.001 
Race (%) 
  
<0.001 
 
<0.001 
White 68.9 64.4  69  
Black 11.7 17.4  15.6  
Hispanic 13.7 12.1  9.9  
Others 5.7 5.9  5.5  
Gender (male, %) 71.2 51.1 <0.001 44.3 <0.001 
Household income 
(%)*   
0.002 
 
0.902 
First quartile 29.5 32.7  29.6  
Second quartile 25 24.3  24.8  
Third quartile 24.8 24.1  25.1  
Fourth quartile 20.7 18.9  20.4  
Admission source 
(%)   
<0.001 
 
<0.001 
Emergency 
department 
56.8 46.9 
 
36.4 
 
Another hospital 4.1 4.9  4.7  
Other facility 
including long-term 
care 
1.9 2.7 
 
2.9 
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Court and law 
enforcement 
0.1 0.2 0.1 
Routine/other 37.2 45.3 55.9 
Hospital location 
(%) 
0.272 0.002 
Rural 10.4 9.4 12.1 
Urban 89.6 90.6 87.9 
Teaching status of 
the hospital (%) 
<0.001 0.053 
Nonteaching 54.5 48.1 52.7 
Teaching 45.5 51.9 47.3 
Hospital bed size 
(%) 
0.001 0.116 
Small 11.6 10.6 12.5 
Medium 26.2 24.2 24.9 
Large 62.3 65.2 62.6 
Region of 
admitting hospital 
(%) 
<0.001 <0.001 
Northeast 19 19.6 20.8 
Midwest 22.1 20.8 23.1 
South 33.9 38.2 37.6 
West 25 21.5 18.5 
Patient 
Disposition (%) 
<0.001 <0.001 
Routine discharge 
to home 
63.1 59.6 66.4 
Short-term hospital 3.5 3.4 2.2 
Skilled nursing 
facility 
15.4 16.4 16.2 
Home healthcare 8.7 12.9 11.7 
Other 9.3 7.7 3.4 
Primary expected 
payer (%) 
<0.001 <0.001 
Medicare 29 46.4 45.3 
Medicaid 21.4 18.9 15 
Private insurance 
(including HMO) 
25.8 23.8 28.8 
Others 23.8 10.9 10.9 
 
*First quartile as $1-$38,999, second as $39,000-$47,999, third as $48,000-62,999 and forth as
$63,000 or more, **compared to alcoholic liver disease
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TABLE 2. Comparison on the prevalence of psychiatric/substance use disorders among 
study cohorts    
Disorder 
Alcoholic liver 
disease 
(N= 74,972) 
Liver diseases 
from other 
etiologies, not 
caused 
byalcohol 
 (N= 350,140) 
P 
value* 
Hospitalized 
patients without 
underlying liver 
diseases 
 (N= 1,447,063) 
P 
value* 
 % N % N % N 
Adjustment 
disorder 
0.58 435 0.42 1,471 0.001 0.60 8,682 0.59 
Anxiety disorder 8.84 6,628 7.54 26,401 0.001 7.91 114,463 0.001 
Attention deficit 
disorder 
0.43 322 0.41 1,436 0.54 0.54 7,814 0.002 
Delirium 
disorder 
2.91 2,182 5.79 20,273 0.001 7.11 102,886 0.001 
Development 
disorder 
0.51 382 0.77 2,696 0.001 0.80 11,577 0.001 
Impulse disorder 0.03 22 0.05 175 0.05 0.12 1,736 0.001 
Mood disorder 24.32 18,233 18.78 65,756 0.001 19.16 277,257 0.001 
Personality 
disorder 
0.96 720 0.73 2,556 0.001 1.28 18,522 0.004 
Schizo and 
psychotic 
disorder 
2.35 1,762 3.16 11,064 0.001 3.44 49,779 0.0001 
Substance abuse 
and its related 
disorder 
12.38 9,282 9.98 34,944 0.001 8.14 117,791 0.001 
Suicide related 
disorder 
2.43 1,822 1.12 3,922 0.001 2.48 35,887 0.72 
Tobacco use 43.83 32,860 27.87 97,584 0.001 26.80 387,813 0.001 
PTSD 1.14 855 0.82 2,871 0.001 0.96 13,892 0.003 
Depression 3.96 2,969 2.12 7,423 0.001 3.21 46,451 .001 
 
*compared to those with alcoholic liver disease
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TABLE 3.  Adjusted odds ratio (aOR) of psychiatric/substance use disorders among 
hospitalized patients with alcoholic liver disease 
Disorder 
aOR (95% CI)  as compared to 
patients with chronic liver 
diseases, not caused by alcohol* 
aOR (95% CI)  as compared to 
hospitalized patientswithout liver 
diseases+ 
Anxiety disorder 1.16 (1.09-1.22) 1.16 (1.10-1.23) 
Mood disorder 1.37 (1.30-1.44) 1.35 (1.28-1.41) 
Depression 1.83 (1.62-2.06) 1.14 (1.02-1.28) 
Personality disorder 1.11 (0.91-1.36) 0.71 (0.58-0.85) 
Substance abuse and 
its related disorder 
1.01 (0.92-1.10) 1.28 (1.20-1.37) 
Suicide- related 
disorder 
1.76 (1.54-2.02) 0.81 (0.73-0.90) 
Tobacco use 1.72 (1.66-1.79) 1.76 (1.70-1.82) 
PTSD 1.17 (1.04-1.32) 1.10 (0.99-1.22) 
 
*using patients with chronic liver diseases, not caused by alcohol as reference
+using hospitalized patients without liver diseases as reference 
  
TABLE 4. Predictors of psychiatric/substance use disorders among hospitalized patients 
with alcoholic liver disease  
Variable 
Adjusted odds ratio, 
aOR (95% CI) 
Age 0.97 (0.96-0.97) 
Race (white as reference 1.0) 
Black 0.80 (0.73-0.88) 
Hispanic 0.56 (0.51-0.61) 
Other 0.61 (0.55-0.68) 
Sex (male as reference 1.0) 
Female 1.58 (1.51-1.66) 
Income quartile (first quartile as reference 1.0)* 
Second quartile 1.00 (0.93-1.08) 
Third quartile 0.97 (0.90-1.04) 
Forth quartile 1.06 (0.98-1.16) 
Hospital region (northeast as reference 1.0) 
Midwest 1.13 (0.98-1.31) 
South 0.85 (0.74-0.97) 
West 0.94 (0.81-1.08) 
Primary expected payer (medicare as reference 1.0) 
Medicaid 0.77 (0.71-0.84) 
Private including HMO 0.67 (0.64-0.73) 
Other 0.64 (0.59-0.70) 
*First quartile as $1-$38,999, second as $39,000-$47,999, third as $48,000-62,999 and forth as
$63,000 or more 
